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Objective: To compare the prevalence of lower extremity peripheral artery disease (PAD) and to assess
whether age-associated progression in ankle-brachial index (ABI) differs between individuals with
chronic immune-mediated inﬂammatory diseases (CIID) and the general population.
Methods: Pooled analysis with data from individuals aged 50 years and older with ABI measurements,
obtained from population-based cross-sectional studies conducted in Catalonia (Spain). Information on
three CIID diagnoses (i.e., inﬂammatory bowel disease, systemic connective tissue disorders, and in-
ﬂammatory polyarthropathies and spondylopathies, considered as one entity for purposes of analysis)
was obtained from electronic medical records. To ascertain the statistical association between PAD and
CIID, logistic regression models were ﬁtted and adjusted for age, sex, and cardiovascular risk factors. We
tested the interaction between age and CIID diagnosis for ABI values.
Results: We included 8799 individuals, 312 (3.6%) with CIID. The age-standardized prevalence of PAD
was higher in the CIID group (12% vs. 6% in general population, p ¼ 0.001), and the model adjusted for
age, sex, and cardiovascular risk factors also showed higher risk in individuals with CIID [Odds Ratio (95%
conﬁdence interval) ¼ 1.65 (1.15e2.38); p ¼ 0.007]. The inﬂammatory polyarthropathies/spondylo-
pathies diagnosis was signiﬁcantly associated with PAD in the fully adjusted model [1.80 (1.18e2.75);
p ¼ 0.006]. The atherosclerotic process was accelerated in individuals with CIID, compared to the general
population (p for interaction < 0.001).
Conclusion: In individuals with CIID, age-standardized prevalence of PAD was signiﬁcantly higher than in
the general population and the atherosclerotic process was accelerated. However, only inﬂammatory
polyarthropathies/spondylopathies was associated with signiﬁcant risk of PAD.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammation plays a key role in coronary artery disease and
other manifestations of atherosclerosis [1]. The prematuregy and Genetics, IMIM (Hos-
r 88, 08003 Barcelona, Spain.
Ireland Ltd. This is an open accessatherosclerosis observed in chronic immune mediated inﬂamma-
tory disorders (CIID) may be a consequence of the chronic inﬂam-
mation inherent to these disorders [2,3]. Due to the long
asymptomatic induction period of atherosclerosis, subclinical in-
dicators of lower extremity peripheral artery disease (PAD), such as
ankle-brachial index (ABI), can provide early risk detection [4,5]. In
addition, pathological ABI is a strong predictor of future cardio-
vascular events [6].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Table 1
Chronic immune mediated inﬂammatory disorders diagnoses included in each
group.
ICD-10 code Title
K50eK52 Noninfective enteritis and colitis
K50 Crohn disease (regional enteritis)
K51 Ulcerative colitis
K52 Other noninfective gastroenteritis and colitis
M05eM14, L40.5 Inﬂammatory polyarthropathies
M05 Seropositive rheumatoid arthritis
M06 Other rheumatoid arthritis
M07 Psoriatic and enteropathic arthropathies
M08 Juvenile arthritis
M09 Juvenile arthritis in diseases classiﬁed elsewhere
M10 Gout
M11 Other crystal arthropathies
M12 Other speciﬁc arthropathies
M13 Other arthritis
L40.5 Arthropathic psoriasis
M30eM35, G635 Systemic connective tissue disorders
M30 Polyarteritis nodosa and related conditions
M31 Other necrotizing vasculopathies
M32 Systemic lupus erythematosus
M33 Dermatopolymyositis
M34 Systemic sclerosis
M35 Other systemic involvement of connective tissue
G63.5 Polyneuropathy in systemic connective tissue disorders
M45eM46 Spondylopathies
M45 Ankylosing spondylitis
M46 Other inﬂammatory spondylopathies
F. Agüero et al. / Atherosclerosis 242 (2015) 1e72PAD is relatively frequent in general population in western
countries [7e9] and the prevalence increased an alarming 13.1%
from 2000 to 2010 [10]. Several reports have shown higher prev-
alence of PAD in individuals with CIID (e.g., systemic lupus ery-
thematosus [11], rheumatoid arthritis [12], or inﬂammatory bowel
diseases [13]). However, these studies have a modest sample size,
participants have usually been recruited in-hospital, and therefore
the patients are more likely to have advanced disease stages. In
contrast, a population-based sample that includes individuals in a
wide range of disease severity and consistently uses the same non-
exposed population would enable a more accurate assessment of
the prevalence of PAD associated with CIID.
The objectives of the studywere: (1) To determine in individuals
aged 50 years and older whether the prevalence of PAD in patients
with CIID is higher than in the general population and (2) to assess
whether age-associated ABI progression differs between in-
dividuals with and without CIID.
2. Methods
2.1. Design and data sources
We carried out a pooled analysis of individual data obtained
from two large, population-based, cross-sectional projects that
included ABI measures: REGICOR (Girona Heart Registry [Registre
Gironí del Cor]) and PERART (Peripheral Artery Disease Study) [7,8].
The REGICOR project is comprised of three cross-sectional studies
carried out in 1995, 2000, and 2005 in Girona Province (Catalonia,
Northeast Spain), which has a population of approximately 674,000
[14]. For the present analysis, we used data from the 2005 study
and from the 2010 follow-up examination of the cohorts recruited
in 1995 and 2000 [15]. The PERART study selected a sample from
patients attending 28 primary healthcare centers within the
metropolitan area of the City of Barcelona and the county of
Barcelones Nord-Maresme between 2006 and 2008. These urban
and semi-rural centers cover a population of approximately
600,000 inhabitants [16]. Both studies used similar methodology
[17]. All participants were duly informed and signed their consent
to participate in the studies, which were approved by the local
ethics committees.
The protocol of the present study, which selected REGICOR and
PERART participants aged 50 years and older, was approved by the
local ethics committee (CEIC-PSMAR).
2.2. Ankle-brachial index measurement
In accordance with current guidelines [6], after 5-min rest we
measured systolic blood pressure in the brachial artery in the
antecubital fossa in the control arm with a continuous Doppler
device, then in the distal calf, using the Doppler probe to determine
systolic blood pressure in the supine position at the right and left
posterior and anterior tibial arteries. Right and left ABI were
calculated as the ratio of the higher of 2 systolic pressures in the
lower limbs (posterior and anterior tibial arteries) to the control
brachial systolic pressures. The lower of the values obtained was
used for analysis. Individuals with ABI1.4 were excluded from the
evaluation because the possible inﬂuence of arterial wall stiffness
made it impossible to discard arterial obstruction. PAD was
considered when an individual presented with ABI <0.9.
2.3. Chronic immune-mediated inﬂammatory disorders
The diagnosis of CIID was obtained from the System for the
Development of Research in Primary Care (SIDIAP) database, which
includes the anonymized electronic medical records ofapproximately 80% of the Catalan population [18]. These diagnoses
were coded according to the International Classiﬁcation of Diseases
10th edition (ICD-10) and divided in four groups: (1) inﬂammatory
bowel diseases, (2) inﬂammatory polyarthropathies, (3) systemic
connective tissue disorders, and (4) spondylopathies (Table 1). We
considered inﬂammatory polyarthropathies and spondylopathies
as a single group since both pathologies mainly present with joint
damage and share the recommendations for cardiovascular risk
prevention [19].
2.4. Other measurements
The PERART and REGICOR questionnaires were based on stan-
dardized World Health Organization (WHO) surveys [17,20]. Soci-
odemographic variables and data on tobacco use, history and
treatments for hypertension, dyslipidemia, and diabetes and his-
tory of cardiovascular disease (e.g. myocardial infarction, angina,
stroke, and intermittent claudication) were recorded. Anthropo-
metric measures were collected by physical examination. Claudi-
cation was assessed using the Edinburgh questionnaire [21].
Symptomatic PAD was considered when an individual presented
with ABI <0.9 and claudication.
Fasting (>10 h) blood samples were analyzed in local labora-
tories that satisﬁed external quality-control requirements [8,14].
Triglycerides, glucose, total cholesterol, high density lipoprotein
(HDL) cholesterol were measured by standard methods. When
triglycerides were <300 mg/dL, low density lipoprotein (LDL)
cholesterol was calculated using the Friedewald formula.
Cardiovascular risk in participants with no history of cardio-
vascular disease was calculated by the Framingham-REGICOR
(Girona Heart Registry [Registre Gironí del Cor]) function vali-
dated for the Spanish population [22]. In addition, the REASON risk
score to select candidates for screening of PAD with ABI was esti-
mated in all participants [23].
2.5. Statistical analysis
Continuous variables were summarized as mean and standard
F. Agüero et al. / Atherosclerosis 242 (2015) 1e7 3deviation, and categorical variables as proportions. Chi-square tests
for categorical variables and ANOVA and Student t test for contin-
uous variables were computed to test differences in the prevalence
of PAD, sociodemographic variables, co-morbidity, and cardiovas-
cular risk factors prevalence, stratiﬁed by disease group (inﬂam-
matory polyarthropathies and spondylopathies, systemic
connective tissue disorders, and inﬂammatory bowel diseases) and
by the presence of PAD.
The prevalence of PAD and of symptomatic PAD was standard-
ized to the age distribution of the European population [24]. To
assess the association between the prevalence of PAD and the
diagnosis of CIID, logistic regression models of increasing
complexity were ﬁtted, adjusting for confounders that were
signiﬁcantly associated with both variables. The analysis included
all individuals with CIID, stratiﬁed by disease group. A sensitivity
analysis was performed for the group of inﬂammatory poly-
arthropathies, excluding individuals with spondylopathies. Addi-
tionally, to assess the association between the prevalence of PAD
and the diagnosis of CIID in individuals with ABI1.4, we adjusted a
logistic model comparing these participants with those with
normal ABI values (0.9 and <1.4).
Finally, we estimated the Pearson correlation between ABI and
age and the interaction between age and ABI values for CIID diag-
nosis in a linear regression model.
3. Results
We included 8799 individuals in our analysis, 3501 (39.8%) from
the PERART Study and 5298 (60.2%) from the REGICOR Study, 4697
(53.4%) women, mean age 64 years (standard deviation ¼ 9). In-
ﬂammatory polyarthropathies was the most prevalent CIID diag-
nosis in both population-based studies (2.4%), followed by
inﬂammatory bowel disease (0.6%), systemic connective tissue
disorders (0.5%) and spondylopathies (0.2%) (Supplementary
Table 1).
Age-standardized PAD prevalence was signiﬁcantly higher in
individuals diagnosed with CIID compared to those without CIID,
but there was no difference in the prevalence of symptomatic
PAD (Fig. 1). In addition, individuals with CIID were signiﬁcantly
older, more often presented with hypertension, diabetes, history
of cardiovascular disease and PAD, and had signiﬁcantly higher
waist circumference, greater 10-year cardiovascular risk, and
lower ABI. Individuals with CIID were also more frequently underFig. 1. Prevalence of overall and symptomatic peripheral artery disease adjusted by
European population [26].treatment for hypertension or dyslipidemia. Finally, individuals
with CIID were more likely to be selected for PAD screening with
ABI, according to REASON estimates, than those without (Table 2).
The prevalence of cardiovascular risk factors in individuals
with and without PAD has been included in Supplementary
Table 2.
The diagnosis of CIID signiﬁcantly increased the risk of PAD in
the model adjusted for age and sex and in the fully adjusted model
(Table 3). In the stratiﬁed analysis, inﬂammatory poly-
arthropathies/spondylopathies was the only group of disorders
signiﬁcantly associated with PAD in both models. We performed a
sensitivity analysis for individuals with inﬂammatory poly-
arthropathies, with similar results. The odds ratios for systemic
connective tissue disorders or inﬂammatory bowel diseases were
1.5 in all instances but did not reach signiﬁcance (Table 4). On the
other hand, individuals with CIID did not presentwith higher risk of
having ABI 1.4 than the general population (Supplementary
Table 3).
Finally, age and ABI showed a signiﬁcant inverse association in
individuals with and without CIID, although this association was
stronger in individuals with CIID. In addition, the interaction be-
tween age and ABI was statistically signiﬁcant (p-value< 0.001) for
CIID diagnosis (Fig. 2).
4. Discussion
The results of this population-based analysis showed an age-
associated increase in risk of PAD and lower ABI in patients with
CIID, compared with the general population. However, inﬂamma-
tory polyarthropathies/spondylopathies was the only group of
disorders that showed an additional risk of PAD not explained by
classical cardiovascular risk factors. On the other hand, the
magnitude of the association between systemic connective tissue
disorders or inﬂammatory bowel diseases and PAD may suggest an
association that was not signiﬁcant because of the low number of
individuals with these diagnoses included in the study. Nonethe-
less, this high PAD risk points out that individuals with CIID are a
vulnerable group not only for intermittent claudication but also for
other cardiovascular events such as myocardial infarction and
stroke [6].
4.1. Atherosclerosis in chronic immune-mediated diseases
CIID have been associated with accelerated atherosclerosis by
several mechanisms such as endothelial dysfunction or systemic
inﬂammation, an association not explained only by the worse car-
diovascular risk proﬁle observed in previous studies [2]. Our study
conﬁrmed this observation and also showed that individuals
diagnosed with CIID and with no history of cardiovascular disease
had higher cardiovascular risk than the general population. These
differences were particularly clear for inﬂammatory poly-
arthropathies alone and also for the combined entity that included
spondylopathies. Several authors have studied the risk factors
associated with PAD prevalence in individuals with rheumatoid
arthritis, the most paradigmatic disease of this group [12,25e27].
The consistent conclusion was that systemic inﬂammation
[12,26,27] and the severity of rheumatoid arthritis, measured with
bone cortical thickness, were related to low ABI in these individuals
[25].
Concurring with previous reports, we found a signiﬁcant asso-
ciation between systemic connective tissue disorders and PAD that
disappeared when the analysis was adjusted for age, sex, and other
potential confounders or intermediate variables [28,29]. The
number of individuals in our sample who were diagnosed with
these disorders was likely insufﬁcient to observe signiﬁcant
Table 2
Characteristics of participants by diagnosis of chronic immune mediated disorders.
Inﬂammatory
polyarthropathies N ¼ 223
Systemic connective tissue
disorders N ¼ 41
Inﬂammatory bowel
diseases N ¼ 48
No chronic immune mediated
disorders N ¼ 8487
p-
value
Age, mean (SD) 67 (9) 70 (7) 66 (8) 64 (9) <0.001
Sex (women), n (%) 85 (38.1) 26 (63.4) 24 (50.0) 4562 (53.8) <0.001
Smoking status, n (%) 0.001
Non smoker 100 (44.8) 26 (65.0) 26 (54.2) 4846 (57.4)
Former smoker 86 (38.6) 11 (27.5) 18 (37.5) 2238 (26.5)
Smoker 37 (16.6) 3 (7.5) 4 (8.3) 1354 (16.1)
Body mass index, mean (SD) 29.5 (4.7) 28.3 (5.0) 28.3 (3.3) 28.4 (4.6) 0.003
Waist circumference, mean (SD) 102.0 (12.5) 101.2 (9.8) 100.5 (8.2) 96.9 (12.4) <0.001
Systolic blood pressure (mmHg), mean
(SD)
140 (20) 137 (21) 133 (17) 136 (20) 0.012
Diastolic blood pressure (mmHg), mean
(SD)
80 (10) 77 (11) 77 (10) 80 (10) 0.083
Hypertension, n (%) 168 (75.3) 30 (73.2) 33 (68.8) 5395 (64.0) 0.003
Treated hypertensiona, n (%) 114 (68.3) 23 (79.3) 25 (80.6) 2926 (54.9) <0.001
Total cholesterol (mg/dl), mean (SD) 209 (39) 206 (30) 216 (42) 216 (41) 0.029
HDL cholesterol (mg/dl), mean (SD) 52 (14) 59 (18) 53 (12) 54 (14) 0.009
LDL cholesterol (mg/dl), mean (SD) 130 (35) 123 (27) 140 (36) 138 (35) 0.001
Triglycerides (mg/dl), median
[interquartile range]
115 [85e154] 109 [88e138] 115 [89e142] 102 [76e140] 0.002
Dyslipidemia, n (%) 118 (52.9) 19 (46.3) 30 (63.8) 4105 (48.6) 0.112
Treated dyslipidemiab, n (%) 68 (58.1) 14 (73.7) 16 (53.3) 1973 (48.6) 0.029
Glycaemia (mg/dl), median
[interquartile range]
99 [92e110] 103 [89e119] 97 [90e109] 97 [89e108] 0.083
Diabetes, n (%) 55 (24.7) 16 (39.0) 16 (33.3) 1773 (20.9) 0.003
Treated diabetesc, n (%) 30 (54.5) 8 (50.0) 5 (31.2) 808 (46.1) 0.381
Anti-platelet or anticoagulant drugs, n
(%)
56 (25.5) 12 (30.0) 7 (14.6) 1712 (20.5) 0.094
10-year cardiovascular riskd, median
[interquartile range]
5.7 [3.8e9.2] 5.1 [2.4e9.2] 4.5 [3.1e7.0] 4.2 [2.6e7.2] <0.001
REASON risk score 4.1%e, n (%) 136 (75.6) 31 (88.6) 35 (81.4) 4745 (63.2) <0.001
History of cardiovascular disease, n (%) 35 (15.7) 4 (9.8) 5 (10.4) 681 (8.0) 0.001
Ankle-brachial index, mean (SD) 1.05 (0.17) 1.03 (0.17) 1.04 (0.15) 1.07 (0.13) 0.003
Peripheral artery disease, n (%) 30 (13.5) 6 (14.6) 5 (10.4) 531 (6.3) <0.001
Symptomatic peripheral artery disease,
n (%)
7 (3.3) 1 (2.6) 0 (0.0) 127 (1.5) 0.146
a In individuals diagnosed with hypertension.
b In individuals diagnosed with dyslipidemia.
c In individuals diagnosed with diabetes.
d In individuals aged 50 to 74 and with no history of cardiovascular disease.
e In individuals aged 50 to 79 and with no history of cardiovascular disease. HDL: High-density lipoprotein. LDL: Low-density lipoprotein. SD: Standard deviation.
Table 3
Adjusted odds ratio of peripheral artery disease (ankle brachial index <0.9 in population with ankle brachial index <1.4) for chronic immune mediated disorders.
Peripheral artery disease
Model 1 Model 2
OR (95% CI) p OR (95% CI) p
Chronic immune mediated inﬂammatory disorder 1.79 (1.26e2.54) 0.001 1.65 (1.15e2.38) 0.007
Age 1.09 (1.07e1.10) <0.001 1.08 (1.07e1.09) <0.001
Sex (ref. men) 0.59 (0.50e0.70) <0.001 1.09 (0.85e1.40) 0.482
Former smoker e e 1.88 (1.44e2.46) <0.001
Current smoker e e 3.41 (2.55e4.56) <0.001
History of cardiovascular disease e e 2.27 (1.81e2.86) <0.001
Body mass index e e 0.98 (0.96e1.00) 0.044
Hypertension e e 1.69 (1.33e2.14) <0.001
Diabetes e e 1.45 (1.19e1.77) <0.001
Dyslipidemia e e 1.28 (1.06e1.54) 0.009
Model 1 has been adjusted for age and sex. Model 2 has been adjusted for age, sex, smoking status, history of cardiovascular disease, body mass index, hypertension, diabetes,
and dyslipidemia.
F. Agüero et al. / Atherosclerosis 242 (2015) 1e74differences. Nonetheless, several authors have pointed out that PAD
predicted the likelihood of more severe systemic lupus erythema-
tosus activity, the most frequent disease in this group, or more
widespread atherosclerotic disease [11,28].
Finally, our study did not ﬁnd a signiﬁcant association between
inﬂammatory bowel disease and PAD in the adjusted models. This
ﬁnding concurs with a recently published meta-analysis [30].4.2. Clinical implications
Asymptomatic PAD, an early functional biomarker of athero-
sclerosis, places individuals at high risk for cardiovascular events
[6]. The age-standardized prevalence of PAD observed in the CIID
population was twice that observed in the general population aged
50 years and older (12% vs. 6%). Therefore, these individuals with
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Fig. 2. Ankle-brachial index by age in individuals with and without chronic inﬂam-
matory immune mediated disorders. Dashed line indicates ankle-brachial index ¼ 0.9.
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functions do not reﬂect actual risk [31]. In our study, individuals
with CIID were more often under treatment for hypertension and
dyslipidemia. In addition, the use of PAD pre-screening functions
could have greater beneﬁts in individuals with PAD, since CIID in-
dividuals presented with signiﬁcantly higher REASON risk scores
[4,23]. Indeed, the detection of ABI has been particularly useful
after initial cardiovascular risk assessment to appropriately
reclassify individuals from moderate to high risk [32].
4.3. Characteristics and limitations of the study
Our study has several limitations. First, a cross-sectional study
design cannot establish causal associations. In addition, selection
bias may affect any cross-sectional study; however, this effect is
likely to be modest in the present study because it was population-
based and participants were not selected on the basis of the pres-
ence or absence of PAD or CIID. Second, identiﬁcation of lower
extremity PADwas based on either claudication or an abnormal ABI
(<0.9). The latter, a surrogatemarker of generalized atherosclerosis,
is the most commonly used test to screen PAD in clinical settings
and to estimate the prevalence of the disorder in epidemiologic
studies [5e9,33]. Third, it was beyond the objectives of our study to
measure blood biomarkers (e.g., systemic inﬂammation, endothe-
lial dysfunction, or prothrombotic state) to explore the potential
mechanisms that may accelerate atherosclerosis in CIID patients
[2,34]. To avoid misclassiﬁcation bias, we used medical diagnosis of
CIID as a robust marker of inﬂammatory status. These diagnoses
were extracted from routinely collected databases that may contain
underreporting; however, the SIDIAP database has been validated
for research in cardiovascular epidemiology [35] and rheumatic
diseases [36]. Indeed, the prevalence of CIID found in SIDIAP
concurred with previous studies [37e39]. Finally, we grouped di-
agnoses in order to increase the number of exposed individuals for
analysis (e.g., inﬂammatory polyarthropathies instead of rheuma-
toid arthritis). Nonetheless, we were not able to detect signiﬁcant
differences in two disease groups, systemic connective tissue dis-
orders and inﬂammatory bowel diseases. Further cohort studies
F. Agüero et al. / Atherosclerosis 242 (2015) 1e76with larger sample sizes are required to conﬁrm the ﬁndings of the
present cross-sectional study.
5. Conclusion
CIID diagnosis increases the risk of PAD. In our study, individuals
diagnosed with CIID presented with higher age-adjusted preva-
lence of PAD and higher magnitude of association between age and
ABI than the general population, suggesting an accelerated
atherosclerotic process. However, the only disease group with
signiﬁcant risk of PAD was inﬂammatory polyarthropathies/spon-
dylopathies. Individuals diagnosed with systemic connective tissue
disorders and inﬂammatory bowel diseases showed a higher PAD
prevalence that was nonsigniﬁcant after adjustment, perhaps
because of the low number of individuals with these disorders
included in the study.
Conﬂict of interest
No conﬂicts of interest.
Acknowledgment
Supported by grants from the Instituto de Salud Carlos III FEDER
(Programa HERACLES RD12/0042; RedIAPP RD12/0005; CP12/
03287), AGAUR (2014 SGR 240 and 2011BP-B00169 postdoctoral
contract to IRD eBeatriu de Pinos Program co-ﬁnanced by the Eu-
ropean Commission), Health Research Fund (FIS 2003/HERMES
PI20471; PI070403; ETES: PI07/90415; FIS11/06765); and Ministry
of Education and Science (SAF2003/1240). The authors acknowl-
edge the System for the Development of Research in Primary Care
(SIDIAP) database, Dr. Albert Escola Campabadal for the expert re-
view on chronic immune mediated inﬂammatory disorders and
also appreciate the revision of the English text by Elaine Lilly PhD.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2015.06.054.
References
[1] G.K. Hansson, Inﬂammation, atherosclerosis, and coronary artery disease,
N. Engl. J. Med. 352 (16) (2005) 1685e1695.
[2] I. Hollan, P.L. Meroni, J.M. Ahearn, J.W. Cohen Tervaert, S. Curran,
C.S. Goodyear, et al., Cardiovascular disease in autoimmune rheumatic dis-
eases, Autoimmun. Rev. 12 (10) (2013) 1004e1015.
[3] G. Murdaca, B.M. Colombo, P. Cagnati, R. Gulli, F. Spano, F. Puppo, Endothelial
dysfunction in rheumatic autoimmune diseases, Atherosclerosis 224 (2)
(2012) 309e317.
[4] M. Grau, J.M. Baena-Díez, F.J. Felix-Redondo, D. Fernandez-Berges, M. Comas-
Cufí, R. Fores, et al., Estimating the risk of peripheral artery disease using
different population strategies, Prev. Med. 57 (4) (2013) 328e333.
[5] L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G. Fowkes,
TASC II working group. Inter-society consensus for the management of pe-
ripheral arterial disease (TASC II), J. Vasc. Surg. 45 (Suppl. S) (2007) S5eS67.
[6] V. Aboyans, M.H. Criqui, P. Abraham, M.A. Allison, M.A. Creager, C. Diehm, et
al., Measurement and interpretation of the ankle-brachial index: a scientiﬁc
statement from the American Heart Association, Circulation 126 (24) (2012)
2890e2909.
[7] R. Ramos, M. Quesada, P. Solanas, I. Subirana, J. Sala, J. Vila, et al., Prevalence of
symptomatic and asymptomatic peripheral arterial disease and the value of
the ankle-brachial index to stratify cardiovascular risk, Eur. J. Vasc. Endovasc.
Surg. 38 (3) (2009) 305e311.
[8] M.T. Alzamora, R. Fores, J.M. Baena-Díez, G. Pera, P. Toran, M. Sorribes, et al.,
The peripheral arterial disease study (PERART/ARTPER): prevalence and risk
factors in the general population, BMC Public Health 10 (2010) 38.
[9] F.J. Felix-Redondo, D. Fernandez-Berges, M. Grau, J.M. Baena-Diez,
J.M. Mostaza, J. Vila, Prevalence and clinical characteristics of peripheral
arterial disease in the study population Hermex, Rev. Esp. Cardiol. Engl. Ed. 65
(8) (2012) 726e733.
[10] F.G. Fowkes, D. Rudan, I. Rudan, V. Aboyans, J.O. Denenberg, M.M. McDermott,et al., Comparison of global estimates of prevalence and risk factors for pe-
ripheral artery disease in 2000 and 2010: a systematic review and analysis,
Lancet 382 (9901) (2013) 1329e1340.
[11] S.R. Schoenfeld, S. Kasturi, K.H. Costenbader, The epidemiology of athero-
sclerotic cardiovascular disease among patients with SLE: a systematic review,
Semin. Arthritis Rheum. 43 (1) (2013) 77e95.
[12] I. del Rincon, R.W. Haas, S. Pogosian, A. Escalante, Lower limb arterial
incompressibility and obstruction in rheumatoid arthritis, Ann. Rheum. Dis.
64 (3) (2005) 425e432.
[13] D. Kohoutova, P. Moravkova, P. Kruzliak, J. Bures, Thromboembolic compli-
cations in inﬂammatory bowel disease, J. Thromb. Thrombol. 39 (4) (2015)
489e498.
[14] M. Grau, I. Subirana, R. Elosua, P. Solanas, R. Ramos, R. Masia, et al., Trends in
cardiovascular risk factor prevalence (1995e2000e2005) in northeastern
Spain, Eur. J. Cardiovasc. Prev. Rehabil. 14 (5) (2007) 653e659.
[15] M. Grau, I. Subirana, D. Agis, R. Ramos, X. Basaga~na, R. Martí, et al., Carotid
intima-media thickness in the Spanish population: reference ranges and as-
sociation with cardiovascular risk factors, Rev. Esp. Cardiol. Engl. Ed. 65 (12)
(2012) 1086e1093.
[16] M.T. Alzamora, J.M. Baena-Díez, M. Sorribes, R. Fores, P. Toran, M. Vicheto, et
al., Peripheral arterial disease study (PERART): prevalence and predictive
values of asymptomatic peripheral arterial occlusive disease related to car-
diovascular morbidity and mortality, BMC Public Health 7 (2007) 348.
[17] Manual of The MONICA Project [Manual en Internet], World Health Organi-
sation, Geneva, 2000 [cited 11 Aug 2014]. Available from: http://www.ktl.ﬁ/
publications/monica/manual/index.htm.
[18] B. Bolíbar, F. Fina Aviles, R. Morros, M. Garcia-Gil Mdel, E. Hermosilla,
R. Ramos, et al., SIDIAP database: electronic clinical records in primary care as
a source of information for epidemiologic research, Med. Clin. Barc. 138 (14)
(2012) 617e621.
[19] M.J. Peters, D.P. Symmons, D. McCarey, B.A. Dijkmans, P. Nicola, T.K. Kvien, et
al., EULAR evidence-based recommendations for cardiovascular risk man-
agement in patients with rheumatoid arthritis and other forms of inﬂam-
matory arthritis, Ann. Rheum. Dis. 69 (2) (2010) 325e331.
[20] J.M. Baena-Díez, M.T. Alzamora-Sas, M. Grau, I. Subirana, J. Vila, P. Toran, et al.,
Validity of the MONICA cardiovascular questionnaire compared with clinical
records, Gac. Sanit. 23 (2009) 519e525.
[21] G.C. Leng, F.G. Fowkes, The Edinburgh claudication questionnaire: an
improved version of the WHO/Rose questionnaire for use in epidemiological
surveys, J. Clin. Epidemiol. 45 (1992) 1101e9.
[22] J. Marrugat, I. Subirana, E. Comín, C. Cabezas, J. Vila, R. Elosua, et al., Validity of
an adaptation of the Framingham cardiovascular risk function: the VERIFICA
Study, J. Epidemiol. Community Health 61 (1) (2007) 40e47.
[23] R. Ramos, J.M. Baena-Díez, M. Quesada, P. Solanas, I. Subirana, J. Sala, et al.,
Derivation and validation of REASON: a risk score identifying candidates to
screen for peripheral arterial disease using ankle brachial index, Atheroscle-
rosis 214 (2) (2011) 474e479.
[24] O.E. Ahmad, C. Boschi-Pinto, A.D. Lopez, C.J.L. Murray, R. Lozano, M. Inoue, Age
Standardization of Rates: A New WHO Standard GPE Discussion Paper Series:
No. 31, World Health Organization, Geneva, 2000.
[25] J.F. Roldan, A. Escalante, I. del Rincon, Impaired arterial function associated
with thinning of cortical bone in rheumatoid arthritis, Arthritis Rheum. 59 (4)
(2008) 523e530.
[26] K.S. Stamatelopoulos, G.D. Kitas, C.M. Papamichael, K. Kyrkou, E. Zampeli,
K. Fragiadaki, et al., Subclinical peripheral arterial disease in rheumatoid
arthritis, Atherosclerosis 212 (1) (2010) 305e309.
[27] Z. Ozbalkan, C. Efe, M. Cesur, S. Ertek, N. Nasiroglu, K. Berneis, et al., An update
on the relationships between rheumatoid arthritis and atherosclerosis,
Atherosclerosis 212 (2) (2010) 377e382.
[28] A.A. Hassan, H.M. Habib, A.A. Eissa, Peripheral arterial disease in patients with
systemic lupus erythematosus: a prospective controlled study, Int. J. Rheum.
Dis. 16 (3) (2013) 319e324.
[29] R.R. June, L.V. Scalzi, Peripheral vascular disease in systemic lupus patients,
J. Clin. Rheumatol. 19 (7) (2013) 367e372.
[30] S. Singh, H. Singh, E.V. Loftus Jr., D.S. Pardi, Risk of cerebrovascular accidents
and ischemic heart disease in patients with inﬂammatory bowel disease: a
systematic review and meta-analysis, Clin. Gastroenterol. Hepatol. 12 (3)
(2014) 382e393.
[31] P.W. Wilson, Evidence of systemic inﬂammation and estimation of coronary
artery disease risk: a population perspective, Am. J. Med. 121 (10 Suppl. 1)
(2008 Oct) S15eS20.
[32] D. Guellec, L. Bressollette, F. Gueguen, S. Jousse-Joulin, T. Marhadour,
V. Devauchelle-Pensec, et al., Is routine ankle-brachial pressure index evalu-
ation useful in rheumatoid arthritis? Jt. Bone Spine 80 (1) (2013) 111e113.
[33] J.S. Lin, C.M. Olson, E.S. Johnson, E.P. Whitlock, The ankle-brachial index for
peripheral artery disease screening and cardiovascular disease prediction
among asymptomatic adults: a systematic evidence review for the U.S. pre-
ventive services task force, Ann. Intern. Med. 159 (5) (2013) 333e341.
[34] A. Arbab-Zadeh, V. Fuster, The myth of the “vulnerable plaque”: transitioning
from a focus on individual lesions to atherosclerotic disease burden for cor-
onary artery disease risk assessment, J. Am. Coll. Cardiol. 65 (8) (2015)
846e855.
[35] R. Ramos, E. Ballo, J. Marrugat, R. Elosua, J. Sala, M. Grau, et al., Validity for use
in research on vascular diseases of the SIDIAP (Information System for the
Development of Research in Primary Care): the EMMA study, Rev. Esp.
F. Agüero et al. / Atherosclerosis 242 (2015) 1e7 7Cardiol. Engl. Ed. 65 (1) (2012) 29e37.
[36] F. Fina-Aviles, M. Medina-Peralta, L. Mendez-Boo, E. Hermosilla, J.M. Elorza,
M. Garcia-Gil, et al., The descriptive epidemiology of rheumatoid arthritis in
Catalonia: a retrospective study using routinely collected data, Clin. Rheu-
matol. (2015) (in press).
[37] L. Carmona, V. Villaverde, C. Hernandez-García, J. Ballina, R. Gabriel, A. Laffon,
EPISER Study Group, The prevalence of rheumatoid arthritis in the general
population of Spain, Rheumatol. Oxf. 41 (1) (2002) 88e95.[38] P. Lopez, L. Mozo, C. Gutierrez, A. Suarez, Epidemiology of systemic lupus
erythematosus in a northern Spanish population: gender and age inﬂuence on
immunological features, Lupus 12 (11) (2003) 860e865.
[39] C. Saro Gismera, S. Riestra Menendez, R. Sanchez Fernandez, A. Milla Crespo,
M. Lacort Fernandez, G. Argüelles Fernandez, et al., Epidemiology in inﬂam-
matory bowel disease in ﬁve areas of Asturias. Spain, Ann. Med. Intern. 20 (5)
(2003) 232e238.
